Here are four things to know.
1. The company reported $5.944 billion in worldwide sales for the third quarter, an 18.4 percent year-over-year increase.
2. AbbVie’s Viekira global sales for the quarter were $469 million. The HCV drug is now approved in 61 countries.
3. The company’s net interest expense for the quarter was $197 million.
4. AbbVie’s diluted earnings per share for the third quarter were $1.31, up approximately 27 percent.
More articles on gastroenterology:
Lovelace Medical Group adds Dr. Julie Farrer: 3 things to know
Global endoscopy market to reach $9.7B by 2021: 5 key trends
The biggest challenges for GI in 2016: 3 gastroenterologists weigh in
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.